South Africa’s Trial Sites: An overview of HIV prevention research and demonstration sites in 2017, by location and intervention.
South African HIV Prevention Research and Demonstration Sites
Evolving Context for HIV Prevention Research (Map)
A global map showing selected HIV prevention research and oral PrEP status.
Fighting HIV Drug Resistance in Uganda
AVAC Fellow Moses Supercharger has this primer on the upward trend of HIV drug resistance in Uganda, with action items for advocates.
Global HIV Prevention R&D Investment by Technology Category, 2000-2016
In 2016, funding for HIV prevention R&D decreased by 3 percent (US$35 million) from the previous year, falling to US$1.17 billion. Funding in 2016 signals the lowest annual investment in HIV prevention R&D in more than a decade.
Composition of the Global HIV Prevention R&D Investment Base, 2015-2016
The call for a more diverse base of funders in the prevention R&D landscape is not a new one, but recent trends display greater polarization and a more extreme funding imbalance. In 2016, 75 percent of the overall funding came from the US public sector. Together, the US public sector and the BMGF represented 88 percent of the total global investment in 2016, compared to 81 percent in 2015.
Excerpted from our HIV prevention research tracking report, visit here for all graphics from the report.
HIV Prevention R&D Trial Participants by Region, 2016
HIV prevention research cannot be conducted without those who volunteer to participate in clinical trials or without the engagement of communities in which those trials take place. In 2016, there were almost 700,000 participants in HIV prevention research trials, primarily based in sites with high HIV/AIDS burdens in Africa, Asia, Latin America and the US.
Excerpted from our HIV prevention research tracking report, visit here for all graphics from the report.
HIV Prevention Research & Development Investments, 2000–2016: Investment priorities to fund innovation in a challenging global health landscape
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2016, funding for HIV prevention R&D decreased by US$35 million from the previous year to a total of US$1.17 billion. This marks the lowest recorded annual investment in more than a decade. While investments toward research in preventive vaccines, PrEP and medical male circumcision increased in 2016, funding for microbicides, treatment as prevention, female condoms and prevention of vertical transmission decreased.
Global Investment in HIV Cure Research and Development in 2016: Funding for a cure remains a priority
Don’t miss this report looking at investment in cure research in 2016. It’s part of the annual report on investment in research and development that AVAC produces as a member of the Resource Tracking for HIV Prevention Research & Development Working Group.
Hormonal Contraceptive Methods and HIV: Research gaps and programmatic priorities
This article in Contraception summarizes key findings and conclusions from a December 2015 meeting convened by WHO on the research agenda for hormonal contraception and HIV.
PrEP 101 Presentation from US Women & PrEP Working Group
Created by the US Women and PrEP Working Group, this PowerPoint is intended to help make quality, basic presentations on PrEP to community members.